

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-16. canceled.

Claim 17. (currently amended): A method for treating a patient in need of treatment for a cardiac disorder, comprising the steps of:

providing a patient in need of treatment for a cardiac disorder; and

administering to said patient an effective amount of a n-heptanoic ~~fatty acid composition~~  
selected from hexanoate, 4-methylhexanoate, 4-methylhexenoate, 3-hydroxy-4-methylhexanoate;  
5-methylhexanoate, 5-methylhexenoate and 3-hydroxy- 5 – methylhexanoate to provide relief to  
said patient from said cardiac disorder selected from cardiac muscle weakness or cardiac  
myopathy.

Claim 18. Cancelled

Claim 19. (currently amended): The method of Claim 17, wherein said n-heptanoic ~~fatty acid~~  
~~composition is bound to comprises~~ a triglyceride comprising at least one selected from 4-  
methylhexanoate, 4-methylhexenoate, 3-hydroxy-4-methylhexanoate; 5-methylhexanoate, 5-  
methylhexenoate and 3-hydroxy-5– methylhexanoate comprising n-heptanoic acid.

Claim 20. (previously presented): The method of Claim 19, wherein said triglyceride comprises  
triheptanoin.

Claim 21-22 cancelled

Claim 23. (currently amended): The method of any of Claims 17, 19, or 20, 21, or 22, wherein  
said cardiac disorder is cardiac muscle weakness.

Claim 24. (currently amended): The method of any of Claims 17, 19, or 20, 21, or 22, wherein  
said cardiac disorder is cardiac myopathy.

Claim 25. (currently amended): The method of any of Claims 17, 19, ~~or 20, 21, or 22~~, wherein said cardiac disorder comprises a reduced efficiency of a metabolic pathway of heart tissue.

Claim 26. (currently amended): The method of any of Claims 17, 19, ~~or 20, 21, or 22~~, wherein said composition is adapted for consumption in one or more doses, and said doses comprise about 15 to about 40% of the dietary caloric requirement for said patient for 24 hours.

Claim 27. (previously presented): The method of Claim 23, wherein said composition is adapted for consumption in one or more doses, and said doses comprise about 15 to about 40% of the dietary caloric requirement for said patient for 24 hours.

Claim 28. (previously presented): The method of Claim 24, wherein said composition is adapted for consumption in one or more doses, and said doses comprise about 15 to about 40% of the dietary caloric requirement for said patient for 24 hours.

Claim 29. (previously presented): The method of Claim 25, wherein said composition is adapted for consumption in one or more doses, and said doses comprise about 15 to about 40% of the dietary caloric requirement for said patient for 24 hours.

Claim 30. (currently amended): The method of any of Claims 17, 19, ~~or 20, 21, or 22~~, wherein said composition is adapted for consumption in one or more doses, and said doses comprise about 20 to about 35% of the dietary caloric requirement for said patient for 24 hours.

Claim 31. (previously presented): The method of Claim 23, wherein said composition is adapted for consumption in one or more doses, and said doses comprise about 20 to about 35% of the dietary caloric requirement for said patient for 24 hours.

Claim 32. (previously presented): The method of Claim 24, wherein said composition is adapted for consumption in one or more doses, and said doses comprise about 20 to about 35% of the dietary caloric requirement for said patient for 24 hours.

Claim 33. (previously presented): The method of Claim 25, wherein said composition is adapted for consumption in one or more doses, and said doses comprise about 20 to about 35% of the dietary caloric requirement for said patient for 24 hours.

Claim 34. (currently amended): The method of any of Claims 17, 19, or 20, 21, or 22, wherein said composition is administered via enteral administration.

Claim 35. (previously presented): The method of Claim 23, wherein said composition is administered via enteral administration.

Claim 36. (previously presented): The method of Claim 24, wherein said composition is administered via enteral administration.

Claim 37. (previously presented): The method of Claim 25, wherein said composition is administered via enteral administration.

Claim 38. (currently amended): The method of any of Claims 17, 19, or 20, 21, or 22, wherein said composition is administered via parenteral administration.

Claim 39. (previously presented): The method of Claim 23, wherein said composition is administered via parenteral administration.

Claim 40. (previously presented): The method of Claim 24, wherein said composition is administered via parenteral administration.

Claim 41. (previously presented): The method of Claim 25, wherein said composition is administered via parenteral administration.

Claim 42. (currently amended): A method for treating a patient in need of treatment for a cardiac disorder, comprising the steps of:

administering to said patient an effective amount of a n-heptanoic fatty acid composition to provide relief to said patient, wherein said composition is provided in an amount about 15 to about 40% of the dietary caloric requirement for said patient for 24 hours.

Claim 43. (previously presented): The method of Claim 42, wherein said composition is administered via enteral administration.

Claim 44. (previously presented): The method of Claim 43, wherein said enteral administration

is orally.

Claim 45. (previously presented): The method of Claim 43, wherein enteral administration is via a nasogastric tube.

Claim 46. (previously presented): The method of Claim 42, wherein said composition is administered via parenteral administration.

Claim 47. (currently amended): A method for providing fuel to heart tissue of a patient, comprising

administering to said patient a n-heptanoic fatty acid composition selected from hexanoate, 4-methylhexanoate, 4-methylhexenoate, 3-hydroxy-4-methylhexanoate; 5-methylhexanoate, 5-methylhexenoate and 3-hydroxy- 5 – methylhexanoate whereby said heart tissue rapidly obtains nutrition from the n-heptanoic acid composition through an odd carbon fatty acid metabolism.

Claim 48 cancelled

Claim 49. (previously presented): The method of Claim 47, wherein said n-heptanoic acid composition comprises a triglyceride comprising n-heptanoic acid.

Claim 50-52. cancelled

Claim 53. (currently amended): A method for treating a patient in need of treatment for a severe translocase deficiency, comprising the steps of:

providing a patient suffering from one or more symptoms of severe translocase deficiency; and

administering to the patient a therapeutically effective amount of a n-heptanoic acid composition consisting essentially of comprising n-heptanoic acid, triheptanoic, 4-methylhexanoate, 4-methylhexenoate, 3-hydroxy-4-methylhexanoate; 5-methylhexanoate, 5-methylhexenoate and 3-hydroxy-5-methylhexanoate or combination thereof sufficient to overcome the severe translocase deficiency.

Claim 54. (previously presented): The method of Claim 53, wherein the n-heptanoic acid composition comprises a triglyceride.

Claim 55. (previously presented): The method of Claim 53, wherein the therapeutically effective amount comprises between 15 and 40% of the daily dietary caloric requirement for the patient.

Claim 56. (previously presented): The method of Claim 53, wherein the therapeutically effective amount comprises between 20 and 35% of the daily dietary caloric requirement for the patient.

Claim 57. (previously presented): The method of any of Claims 53, wherein the administering is oral, enteral or combination thereof.